BOSTON, March 5, 2021 /PRNewswire/ -- NeuroBo
Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage
biotechnology company, today announced that Company management will
participate in the upcoming H.C. Wainwright Global Life Sciences
Conference taking place virtually from March
9-10, 2021.
Akash Bakshi, Senior Vice
President and Chief Operating Officer of NeuroBo and Seth Reno, Commercial Advisor of NeuroBo, will
present a corporate overview at the conference, including an update
on the status of the ongoing phase 2/3 study of lead program,
ANA001, in moderate and severe COVID-19 patients.
The presentation will be available beginning March 9, at 7:00 am
ET. A webcast of the presentation will be available on the
"Events and Presentations" section of NeuroBo's website at:
neurobopharma.com/events-presentations. An archived replay will be
available for a period of 90 days after the conference.
About NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology
company focused on developing and commercializing multi-modal
disease-modifying therapies for viral, neuropathic, and
neurodegenerative diseases, has a current portfolio of four
drug candidates. The company's recently acquired ANA001 candidate
is a proprietary oral niclosamide formulation in development as a
treatment for patients with moderate to severe COVID-19 (patients
not requiring ventilators). Niclosamide is a potential oral
antiviral and anti-inflammatory agent with a long history of use
and a well-understood safety profile in humans. ANA001 is currently
being studied in a 60-subject Phase 2/3 clinical trial conducted at
up to 20 clinical sites in the U.S. Niclosamide has demonstrated
both antiviral and immunomodulatory activity with possible
downstream effects on coagulation abnormalities observed in
COVID-19. The company's NB-01 candidate has been shown in a Phase 2
study to significantly reduce pain symptoms associated with painful
diabetic neuropathy (PDN), with a superior safety profile when
compared to currently available treatments. Due to global COVID-19
crisis, a planned Phase 3 study was postponed. In the interim,
NeuroBo is exploring a potential orphan drug indication targeting
chronic pain for NB-01. NeuroBo's NB-02 drug candidate is focused
on the treatment of Alzheimer's disease and neurodegenerative
diseases associated with the pathological dysfunction of tau
proteins in the brain. The company's fourth program, Gemcabene, was
developed for the treatment of dyslipidemia, a serious medical
condition that increases the risk of life-threatening
cardiovascular disease.
For more information
visit: https://www.neurobopharma.com.
Forward Looking Statements
Any statements in this press release that are not statements of
historical fact constitute forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These statements include, but are not limited to,
statements regarding the development timeline for niclosamide for
the treatment of COVID-19, the market size for COVID-19-related
therapeutics and the competitive advantages of ANA001, the
potential benefits of ANA001 as a treatment for patients with
moderate to severe COVID-19 (patients not requiring ventilators),
and potential milestone payments and royalties that may become due
to the former equity holders of ANA under the acquisition
agreement. Forward-looking statements are usually identified by the
use of words, such as "believes," "anticipates," "expects,"
"intends," "plans," "may," "potential," "will," "could" and similar
expressions. Actual results may differ materially from those
indicated by forward-looking statements as a result of various
important factors and risks. These factors, risks and uncertainties
include, but are not limited to: the failure to obtain all of the
benefits or recognize all of the synergies anticipated from the ANA
acquisition; the integration of ANA potentially diverting
management resources from operational matters and other strategic
opportunities; the effect of future milestone payments and
royalties specified in the acquisition agreement on the results of
operations and financial position of NeuroBo; the occurrence of
health epidemics or contagious diseases, such as COVID-19, and
potential effects on NeuroBo's business, clinical trial sites,
supply chain and manufacturing facilities; NeuroBo's ability to
continue as a going concern; the timing of completion of NeuroBo's
planned clinical trials, including with respect to ANA001; the
timing of the availability of data from NeuroBo's clinical trials,
including with respect to ANA001; the clinical utility,
potential benefits and market acceptance of NeuroBo's product
candidates, including ANA001; ; and NeuroBo's need for additional
financing to fulfill its stated goals; and other factors discussed
in the "Risk Factors" section of NeuroBo's Annual Report on Form
10-K and in our other filings with the Securities and Exchange
Commission. In addition, the forward-looking statements included in
this press release represent NeuroBo's views as of the date hereof.
NeuroBo anticipates that subsequent events and developments will
cause its views to change. However, while NeuroBo may elect to
update these forward-looking statements at some point in the
future, NeuroBo specifically disclaims any obligation to do so.
These forward-looking statements should not be relied upon as
representing NeuroBo's views as of any date subsequent to the date
hereof.
Contacts:
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com
View original
content:http://www.prnewswire.com/news-releases/neurobo-pharmaceuticals-to-participate-in-hc-wainwright-global-life-sciences-conference-301241340.html
SOURCE NeuroBo Pharmaceuticals, Inc.